#AMRSOS! GRAM report: “at least 1.27m deaths/year directly attributable to AMR”
17 Sep 2024 update: This is now the first of a 3-part newsletter series! See also part 2 (“R&D Implications: Global Burden of Disease is
20 January 2022
No Comments
Push/Pull
AMR Science-Policy Symposia (ESCMID 2026): Smart policies for lean times
Dear All: ESCMID Global once again held an afternoon of sessions focused on the intersection of AMR-related science and policy. With an overall theme of “Smart
19 April 2026
No Comments
Most current global summary of Pull incentives
Dear All, I was recently asked about a ready summary of the current state of play of Pull incentives around the globe. In response, here
13 April 2025
No Comments
Tragedy of the (Antibiotic) Commons: A true market failure
Dear All, In a 28 Feb 2024 newsletter entitled “How Economists (And Finance Ministers) Think…”, we reviewed an important new paper on the economics of
19 March 2024
No Comments
Progress (at least some!) towards a global pull incentive
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), In the wake of the Sep 2024 UNGA HLM on AMR (UN General
15 September 2025
No Comments
#AMRSOS! AMR could worsen, killing 39m during 2025-2050
Dear All, Just in time for the United Nations General Assembly High-Level Meeting on AMR, the team behind the global burden of disease (GBD) estimates
17 September 2024
No Comments
Pull mechanisms: Private capital can multiply Subscription (Netflix) and TEV models!
Dear All: Three recent papers bring together an instructive perspective on Pull incentives for the #FireExtinguishersOfMedicine. The first two papers survey the available tools and
26 March 2022
No Comments
PASTEUR (v2.0) reintroduced in the US Congress!
Dear All, I’m delighted to be able to say that PASTEUR 2026 was (re)introduced into the US Congress this week! It’s an improved version relative
12 February 2026
No Comments
UK Pull (“Netflix-like”) pilot: STEDI-based QALY value of new antibiotics implies societal value > 10m GBP/year!
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), We’ve written before about the UK’s “Netflix” pilot antibiotic Pull incentive in which England leads
11 April 2022
No Comments
Antibiotic supply chains: Challenges & Opportunities
Dear All, In a report entitled Understanding the Antibiotic Manufacturing Ecosystem: A view of global supply chains, pressure points, and implications for antimicrobial resistance response, the
4 May 2022
No Comments